PaxVax develops vaccines for infectious diseases in what the privately held company calls a "socially responsible' manner. It reports having raised more than $200 million from investors. This includes $105 million in December from Cerberus Capital Management, which is the majority owner.
In December, PaxVax said the U.S. Food and Drug Administration agreed to review an application to approve its vaccine for cholera, Vaxchora. The FDA has already approved one vaccine sold by PaxVax. Called Vivotif, it prevents typhoid fever.